Medacta Group SA (MOVE) - Net Assets
Based on the latest financial reports, Medacta Group SA (MOVE) has net assets worth CHF424.61 Million CHF (≈ $536.82 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF860.76 Million ≈ $1.09 Billion USD) and total liabilities (CHF436.15 Million ≈ $551.42 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Medacta Group SA's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CHF424.61 Million |
| % of Total Assets | 49.33% |
| Annual Growth Rate | 14.92% |
| 5-Year Change | 130.49% |
| 10-Year Change | N/A |
| Growth Volatility | 22.76 |
Medacta Group SA - Net Assets Trend (2015–2024)
This chart illustrates how Medacta Group SA's net assets have evolved over time, based on quarterly financial data. Also explore MOVE asset base for the complete picture of this company's asset base.
Annual Net Assets for Medacta Group SA (2015–2024)
The table below shows the annual net assets of Medacta Group SA from 2015 to 2024. For live valuation and market cap data, see Medacta Group SA market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CHF379.66 Million ≈ $480.00 Million |
+15.04% |
| 2023-12-31 | CHF330.04 Million ≈ $417.26 Million |
+20.16% |
| 2022-12-31 | CHF274.65 Million ≈ $347.24 Million |
+21.32% |
| 2021-12-31 | CHF226.40 Million ≈ $286.23 Million |
+37.45% |
| 2020-12-31 | CHF164.72 Million ≈ $208.25 Million |
+33.66% |
| 2019-12-31 | CHF123.23 Million ≈ $155.80 Million |
+38.36% |
| 2018-12-31 | CHF89.07 Million ≈ $112.61 Million |
-12.39% |
| 2017-12-31 | CHF101.67 Million ≈ $128.54 Million |
-30.78% |
| 2016-12-31 | CHF146.87 Million ≈ $185.69 Million |
+35.30% |
| 2015-12-31 | CHF108.55 Million ≈ $137.24 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Medacta Group SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 231.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CHF346.07 Million | 91.15% |
| Common Stock | CHF1.77 Million | 0.47% |
| Other Comprehensive Income | CHF36.40 Million | 9.59% |
| Total Equity | CHF379.66 Million | 100.00% |
Medacta Group SA Competitors by Market Cap
The table below lists competitors of Medacta Group SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangdong Dongfang Precision Science & Technology Co Ltd
SHE:002611
|
$3.06 Billion |
|
Hawkins Inc
NASDAQ:HWKN
|
$3.06 Billion |
|
Community Bank System Inc
NYSE:CBU
|
$3.07 Billion |
|
Seacoast Banking Corporation of Florida
NASDAQ:SBCF
|
$3.07 Billion |
|
Sunrun Inc
NASDAQ:RUN
|
$3.06 Billion |
|
Quilter PLC
JSE:QLT
|
$3.06 Billion |
|
Lakala Payment Co Ltd
SHE:300773
|
$3.06 Billion |
|
Telefonaktiebolaget LM Ericsson (publ)
ST:ERIC-A
|
$3.06 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medacta Group SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 330,038,000 to 379,664,000, a change of 49,626,000 (15.0%).
- Net income of 72,886,000 contributed positively to equity growth.
- Dividend payments of 11,194,000 reduced retained earnings.
- Share repurchases of 4,788,000 reduced equity.
- Other comprehensive income decreased equity by 7,124,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CHF72.89 Million | +19.2% |
| Dividends Paid | CHF11.19 Million | -2.95% |
| Share Repurchases | CHF4.79 Million | -1.26% |
| Other Comprehensive Income | CHF-7.12 Million | -1.88% |
| Other Changes | CHF-154.00K | -0.04% |
| Total Change | CHF- | 15.04% |
Book Value vs Market Value Analysis
This analysis compares Medacta Group SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.44x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 19.28x to 7.44x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CHF7.34 | CHF141.60 | x |
| 2017-12-31 | CHF5.08 | CHF141.60 | x |
| 2018-12-31 | CHF4.45 | CHF141.60 | x |
| 2019-12-31 | CHF6.16 | CHF141.60 | x |
| 2020-12-31 | CHF8.24 | CHF141.60 | x |
| 2021-12-31 | CHF11.32 | CHF141.60 | x |
| 2022-12-31 | CHF13.74 | CHF141.60 | x |
| 2023-12-31 | CHF16.54 | CHF141.60 | x |
| 2024-12-31 | CHF19.04 | CHF141.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medacta Group SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.20%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.34%
- • Asset Turnover: 0.75x
- • Equity Multiplier: 2.09x
- Recent ROE (19.20%) is below the historical average (24.03%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 26.70% | 17.90% | 0.81x | 1.84x | CHF24.53 Million |
| 2017 | 32.95% | 13.69% | 0.82x | 2.95x | CHF23.33 Million |
| 2018 | 51.37% | 16.78% | 0.75x | 4.10x | CHF36.85 Million |
| 2019 | 9.62% | 3.82% | 0.75x | 3.35x | CHF-464.40K |
| 2020 | 22.52% | 12.26% | 0.68x | 2.68x | CHF20.62 Million |
| 2021 | 22.76% | 14.19% | 0.74x | 2.16x | CHF28.88 Million |
| 2022 | 16.84% | 10.58% | 0.75x | 2.13x | CHF18.78 Million |
| 2023 | 14.35% | 9.27% | 0.73x | 2.11x | CHF14.36 Million |
| 2024 | 19.20% | 12.34% | 0.75x | 2.09x | CHF34.92 Million |
Industry Comparison
This section compares Medacta Group SA's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $107,716,005
- Average return on equity (ROE) among peers: -96.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medacta Group SA (MOVE) | CHF424.61 Million | 26.70% | 1.03x | $3.06 Billion |
| Kuros Biosciences AG (KURN) | $8.24 Million | -301.25% | 7.34x | $988.78 Million |
| Medartis Holding AG (MED) | $-46.95 Million | 0.00% | 0.00x | $1.17 Billion |
| Sonova H Ag (SOON) | $361.86 Million | 11.78% | 1.05x | $10.75 Billion |
About Medacta Group SA
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Latin America, North America, the Asia-Pacific, and Middle East and Africa. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine surgery. Medacta Group SA was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.